AMRX SEC-arkivering - Amneal Pharmaceuticals, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

LEI	549300VV176ZO5WQHZ61
CIK	1723128

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amneal Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2026 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2026 AMNEAL PHARMACEUTICALS, INC.
May 7, 2026	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Prelimi Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒ BRIDGEWATER, N
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2026 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2026 AMNEAL PHARMACEUTICALS, INC.
April 23, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
April 22, 2026	EX-10.1	RESTRICTIVE COVENANTS AGREEMENT EX-10.1 Exhibit 10.1 RESTRICTIVE COVENANTS AGREEMENT This RESTRICTIVE COVENANTS AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2026 by and between Amneal Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), and Chirag Patel, an individual (“CP”). Each of Buyer and CP is sometimes hereinafter referred to as a “Party” and, collectively, the “Parties”. WITNESSETH: WHEREAS,
April 22, 2026	EX-2.1	MEMBERSHIP INTEREST PURCHASE AGREEMENT dated as of April 21, 2026 by and among KASHIV BIOSCIENCES, LLC, (the “Company”), THE “SELLERS” NAMED HEREIN, KB SELLER REPRESENTATIVE, LLC (the “Seller Representative”), AMNEAL PHARMACEUTICALS, INC. EX-2.1 Exhibit 2.1 MEMBERSHIP INTEREST PURCHASE AGREEMENT dated as of April 21, 2026 by and among KASHIV BIOSCIENCES, LLC, (the “Company”), THE “SELLERS” NAMED HEREIN, KB SELLER REPRESENTATIVE, LLC (the “Seller Representative”), and AMNEAL PHARMACEUTICALS, INC. (“Buyer”) TABLE OF CONTENTS Page ARTICLE I THE SALE 2 1.1 The Sale 2 1.2 Purchase Price 2 1.3 Payments and Deliveries at Closing 2 1.4 Con
April 22, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2026 AMNEAL PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2026 AMNEAL PHARMACEUTICALS, INC.
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
April 22, 2026	EX-99.1	Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance – Acquisition Positions Amneal to Capitalize on $300B+ Global Biolog EX-99.1 Exhibit 99.1 Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance – Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued G
April 22, 2026	EX-10.2	RESTRICTIVE COVENANTS AGREEMENT EX-10.2 Exhibit 10.2 RESTRICTIVE COVENANTS AGREEMENT This RESTRICTIVE COVENANTS AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2026 by and between Amneal Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), and Chintu Patel, an individual (“CP”). Each of Buyer and CP is sometimes hereinafter referred to as a “Party” and, collectively, the “Parties”. WITNESSETH: WHEREAS,
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
April 22, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2026 AMNEAL PHARMACEUTICA DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2026 AMNEAL PHARMACEUTICALS, INC.
March 25, 2026	DEF 14A	Notice of 2026 Annual Meeting of Stockholders and Proxy Statement Our Fellow Stockholders, Stakeholders and Colleagues, Safe Harbor Statement Corporate Governance Proposal 1 Election of Directors Our Management Executive Compensation Pay Ratio Disclo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 25, 2026	DEF 14A	DEFINITIVE PROXY STATEMENT Voting Your vote is important, and you are invited to attend the annual meeting. Whether or not you expect to attend the annual meeting, we encourage you to vote as soon as possible. To ensure your shares are voted, you may vote your shares in advance of the meeting over the internet, by telephone or, if you requested to receive printed proxy materials, by mailing a proxy or voting instruction car
March 25, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) AMNEAL PHARMACEUTICALS, INC. - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitt
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2026 AMNEAL PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2026 AMNEAL PHARMACEUTICALS, INC.
February 27, 2026	EX-21.1	Amneal Pharmaceuticals, Inc. Exhibit 21.1 Amneal Pharmaceuticals, Inc. Subsidiaries of the Registrant as of December 31, 2025: Name of Subsidiary Jurisdiction of Incorporation or Organization Amedra Pharmaceuticals LLC Delaware Amneal Healthcare Private Ltd. India Amneal Complex Products, Research LLC Delaware Amneal EU, Limited Ireland Amneal Ireland Limited Ireland Amneal Ireland Holdings Limited Ireland Amneal Oncology Pri
February 27, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, In
February 27, 2026	EX-99.1	AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Dil Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $
February 27, 2026	EX-10.14	AMNEAL PHARMACEUTICALS, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE AMNEAL PHARMACEUTICALS, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the target number of Performance Restricted Stock Units set forth below (the “PSUs”).
February 3, 2026	EX-10.1	AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT Execution Version AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT, dated as of February 2, 2026 (this “Amendment”), to the Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”; as amended by this Amendment and further
February 3, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2026 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2026 AMNEAL PHARMACEUTICALS, INC.
January 28, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2026 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2026 AMNEAL PHARMACEUTICALS, INC.
January 13, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2026 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2026 AMNEAL PHARMACEUTICALS, INC.
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceut
October 30, 2025	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, October 30, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced it
October 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2025 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2025 AMNEAL PHARMACEUTICALS, INC.
August 27, 2025	144	144 144 0001781149 XXXXXXXX LIVE 0001723128 Amneal Pharmaceuticals, Inc. 001-38485 400 CROSSING BLVD BRIDGEWATER NJ 08807 (908) 947-3120 Kiely John Director CLASS A MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510 32000 293810.00 314079309 08/27/2025 NASDAQ CLASS A 05/10/2024 EQUITY COMPENSATION AMNEAL PHARMACEUTICALS N 32000 05/10/2024 EQUITY COMPENSATION Y 08/27/2025 JOHN KIELY
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals
August 7, 2025	EX-10.3	Modification No. 3 to Employment Agreement, dated March 11, 2020, by and among Amneal Pharmaceuticals, Inc. and Anastasios (Tasos) G. Konidaris, dated April 1, 2025.* † MODIFICATION No. 3 to EMPLOYMENT AGREEMENT ENTERED MARCH 11, 2020 This Modification, effective as of April 1, 2025, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Anastasios (Tasos) G. Konidaris (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment Agreement dated March 11, 2020, a complete cop
August 7, 2025	EX-10.5	Amended and Restated Revolving Credit and Term Loan Agreement, dated April 9, 2025, by and among Rondo Intermediate Holdings and LLC and Rondo Holdings, LLC, several banks and other financial institutions and lenders from time to time party hereto and Trust Bank, in its capacity as administrative agent for the Lenders and the Issuing bank.* projectrondo-arrevolving Execution Version AMERICAS 129648577 AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT dated as of January 31, 2020 and amended and restated as of April 9, 2025 among RONDO INTERMEDIATE HOLDINGS, LLC as Borrower, RONDO HOLDINGS, LLC, as Holdings, THE LENDERS FROM TIME TO TIME PARTY HERETO, and TRUIST BANK as Administrative Agent TRUIST SECURITIES, INC.
August 7, 2025	EX-10.4	Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description AMNEAL PHARMACEUTICALS LLC SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Introduction This Amneal Pharmaceuticals LLC Severance Plan (the “Plan”) is established to provide for payment of severance benefits by Amneal Pharmaceuticals LLC (the “Company”) to eligible Participants whose employment with the Company Group (as defined below) is terminated for reasons described under the conditions below.
August 7, 2025	EX-10.2	Modification No. 3 to Employment Agreement, dated February 6, 2018, by and among Amneal Pharmaceuticals, Inc. and Andrew Boyer, dated April 1, 2025.* † MODIFICATION No. 3 to EMPLOYMENT AGREEMENT ENTERED FEBRUARY 6, 2018 This Modification, effective as of April 1, 2025, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Andrew Boyer (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment Agreement dated February 6, 2018, a complete copy of which is a
August 7, 2025	EX-10.1	Modification No. 2 to Employment Agreement, dated July 29, 2020, by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated April 1, 2025.* † MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED JULY 29, 2020 This Modification, effective as of April 1, 2025, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Nikita Shah (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment Agreement dated July 29, 2020, a complete copy of which is attached
August 5, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 AMNEAL PHARMACEUTICALS, INC.
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 AMNEAL PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 AMNEAL PHARMACEUTICALS, INC.
August 5, 2025	EX-99.1	AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS ‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Yea Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS ‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 ‒ BRIDGEWATER, NJ, August 5, 2025 - Amneal Phar
August 1, 2025	EX-4.1	Indenture, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent. Exhibit 4.1 INDENTURE Dated as of August 1, 2025 Among Amneal Pharmaceuticals LLC, as Issuer, the Guarantors party hereto and Wilmington Savings Fund Society, FSB as Trustee and as Collateral Agent 6.875% SENIOR SECURED NOTES DUE 2032 TABLE OF CONTENTS Page Article I Definitions and Incorporation by Reference 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 71 Section 1.03. Rules of
August 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2025 AMNEAL PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2025 AMNEAL PHARMACEUTICALS, INC.
August 1, 2025	EX-10.2	Amendment No. 2 to Revolving Credit Agreement and Amendment No. 2 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the other loan parties party hereto, the lenders party hereto and Truist Bank, as administrative agent and collateral agent. Exhibit 10.2 AMENDMENT NO. 2 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 2 TO COLLATERAL AGREEMENT This AMENDMENT NO. 2 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 2 TO COLLATERAL AGREEMENT, dated as of August 1, 2025 (this “Amendment No. 2”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the other Loan Parties party hereto,
August 1, 2025	EX-10.1	Amendment No. 1 to Term Loan Credit Agreement and Amendment No. 1 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the lenders party thereto, JPMorgan Chase Bank, NA., as administrative agent and collateral agent, and the bookrunners and arrangers party thereto. Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT AND AMENDMENT NO. 1 TO TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT AND AMENDMENT NO. 1 TO TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT, dated as of August 1, 2025 (this “Amendment”), to (i) the Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, s
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2025 AMNEAL PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2025 AMNEAL PHARMACEUTICALS, INC.
July 21, 2025	EX-99.1	Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 Exhibit 99.1 Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 July 21, 2025 BRIDGEWATER, N.J.-(BUSINESS WIRE)-Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year t
July 21, 2025	EX-99.1	AMNEAL REPORTS CERTAIN PRELIMINARY SECOND QUARTER 2025 FINANCIAL RESULTS – Results Reflect Continued Financial Strength and Deleveraging – Exhibit 99.1 AMNEAL REPORTS CERTAIN PRELIMINARY SECOND QUARTER 2025 FINANCIAL RESULTS – Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, NJ, July 21, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025. The Company plans to report actual
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2025 AMNEAL PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2025 AMNEAL PHARMACEUTICALS, INC.
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2025 AMNEAL PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2025 AMNEAL PHARMACEUTICALS, INC.
May 8, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 AMNEAL PHARMACEUTICALS, INC.
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 7, 2025	EX-10.1	, dated March 1, 2025, by and among Amneal Pharmaceuticals, Inc. and Jason Daly. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective as of March 1, 2025, by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Jason Daly (the “Executive” and, collectively with the Company, the “Parties”). WITNESSETH: WHEREAS, the Executive has been employed as Senior Vice President, Chief Legal Officer & Corporate Secretary of the Company; WHEREAS, the
May 2, 2025	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Ye Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, May 2, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its
May 2, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2025 AMNEAL PHARMACEUTICALS, INC.
March 25, 2025	DEF 14A	Safe Harbor Statement Corporate Governance Proposal 1 Election of Directors Our Management Executive Compensation Pay Ratio Disclosure Pay Versus Performance Disclosure Proposal 2 Advisory Vote on Executive Compensation Proposal 3 Advisory Vote on th UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 6, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2025 AMNEAL PHARMACEUTICALS, INC.
February 28, 2025	EX-99.1	AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Ne
February 28, 2025	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Amneal Pharmaceuticals, Inc. Subsidiaries of the Registrant as of December 31, 2024: Name of Subsidiary Jurisdiction of Incorporation or Organization Amedra Pharmaceuticals LLC Delaware Amneal Healthcare Private Ltd. India Amneal Complex Products, Research LLC Delaware Amneal EU, Limited Ireland Amneal Ireland Limited Ireland Amneal Ireland Holdings Limited Ireland Amneal Oncology Pri
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, In
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 AMNEAL PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 AMNEAL PHARMACEUTICALS, INC.
February 28, 2025	EX-10.14	Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice. Exhibit 10.14 AMNEAL PHARMACEUTICALS, INC. 2018 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the target number of Performance Restricted Stock Units set forth below
February 28, 2025	EX-19.1	Insider Trading Global Policy. TITLE: INSIDER TRADING – GLOBAL POLICY LEGACY DOCUMENT NO: POLICY-COMP-0021 DOCUMENT NUMBER: GLOBAL-POLICY-LEGAL-0020 OWNING DEPARTMENT: LEGAL EFFECTIVE DATE: August 7, 2023 PAGE 1 of 8 AMNEAL PHARMACEUTICALS, INC.
January 15, 2025	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 15, 2025 AMNEAL PHARMACEUTICALS, INC.
November 14, 2024	SC 13G/A	AMRX / Amneal Pharmaceuticals, Inc. / Mahesh Akram - SC 13G/A Passive Investment SC 13G/A 1 sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L10
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceut
November 12, 2024	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Gu Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, November 8, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its
November 12, 2024	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
November 8, 2024	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Gu Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, November 8, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2024 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2024 AMNEAL PHARMACEUTICALS, INC.
October 31, 2024	EX-99.5	Form of Account Control Agreement, dated as of October 29, 2024, by and among each of the Borrowers, UBS and UBS Financial Services Inc. EX-99.5 2 exh99-5.htm PLEDGE AND SECURITY AGREEMENT, DATED AS OF MAY 9, 2024, BY AND BETWEEN TI SIE 2 LLC AND CITIBANK, N.A. EXHIBIT 5 Modified from UBS Form UBS FINANCIAL SERVICES INC. A C C O U N T C O N T R O L A G R E E M E N T This Agreement is between UBS Financial Services Inc. (“UBSFS”), the party or parties signing this Agreement as Client where indicated below (together and individually,
October 31, 2024	SC 13D/A	AMRX / Amneal Pharmaceuticals, Inc. / Patel Chirag K. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 sc13d-a.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Chirag Patel c/o McCabe Heidrich & Wong, PC Attention: Christine Krentz 4 Ga
October 31, 2024	EX-99.6	Form of Letter Agreement, dates as of October 29, 2024, by and among each of the Borrowers, UBS and the New Issuer. EX-99.6 3 exh99-6.htm ISSUER LETTER AGREEMENT, DATED AS OF MAY 9, 2024, BY AND BETWEEN AMNEAL PHARMACEUTICALS, INC. AND CITIBANK, N.A. EXHIBIT 6 October 29, 2024 Amneal Pharceuticals, Inc. 400 Crossing Boulevard Bridgewater, NJ 08807 Chirag Patel 391 Mendham Road Bernardsville, NJ 07924 Priti Patel 391 Mendham Road Bernardsville, NJ 07924 The Chirag Patel Revocable Trust 391 Mendham Road Bernardsv
October 1, 2024	EX-99.1	Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next- Generation Medicines for Obesity and Metabolic Diseases Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing netw Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next- Generation Medicines for Obesity and Metabolic Diseases Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonists Agreement provides Amneal with a new high-growth vector to drive long-term value creation Metsera gains high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable rapid product development and anticipated commercial launches October 1, 2024 BRIDGEWATER, N.
October 1, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2024 AMNEAL PHARMACEUTICALS, INC.
August 9, 2024	EX-99.2	AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Exhibit 99.2 AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT® U.S. FDA approval represents an exciting new long-term growth driver ‒ BRIDGEWATER, NJ, August 9, 2024 - Amneal Ph
August 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 AMNEAL PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 AMNEAL PHARMACEUTICALS, INC.
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals
August 9, 2024	EX-99.1	Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to be launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million peopl Exhibit 99.1 Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to be launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently living with Parkinson’s disease in
May 13, 2024	SC 13D/A	AMRX / Amneal Pharmaceuticals, Inc. / Patel Tushar Bhikhubhai - SCHEDULE 13D/A Activist Investment SC 13D/A 1 sc13d-a.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Tushar Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpor
May 13, 2024	EX-99.6	Issuer Letter Agreement, dated as of May 9, 2024, by and between Amneal Pharmaceuticals, Inc. and Citibank, N.A. EX-99.6 3 exh99-6.htm ISSUER LETTER AGREEMENT, DATED AS OF MAY 9, 2024, BY AND BETWEEN AMNEAL PHARMACEUTICALS, INC. AND CITIBANK, N.A. EXHIBIT 6 Issuer Letter Agreement May 9, 2024 Citibank, N.A. 388 Greenwich Street New York, NY 10013 Attn: [ ] Ladies and Gentlemen: Reference is made to (i) the Margin Loan Agreement dated as of May 9, 2024 among TI SIE 2, LLC (“Borrower”), as Borrower, Citibank,
May 13, 2024	EX-99.5	Pledge and Security Agreement, dated as of May 9, 2024, by and between TI SIE 2 LLC and Citibank, N.A. EX-99.5 2 exh99-5.htm PLEDGE AND SECURITY AGREEMENT, DATED AS OF MAY 9, 2024, BY AND BETWEEN TI SIE 2 LLC AND CITIBANK, N.A. EXHIBIT 5 PLEDGE AND SECURITY AGREEMENT This Pledge and Security Agreement (this “Security Agreement”) is entered into as of May 9, 2024, by and among Citibank, N.A., as collateral agent (“Collateral Agent”) for Citibank, N.A. (the “Relevant Lender”) and any Agented Lender a
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 AMNEAL PHARMACEUTICALS, INC.
May 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 AMNEAL PHARMACEUTICALS, INC.
May 3, 2024	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settle Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒ ‒ Affirming 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, May
April 24, 2024	SC 13G/A	AMRX / Amneal Pharmaceuticals, Inc. / Fosun International Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm249671d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value US$0.01 per share (Title of Class of Securities) 03168L105 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this S
March 22, 2024	DEF 14A	Notice of 2024 To UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 22, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 14, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, In
March 14, 2024	EX-4.2	Description of Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General The following is a summary of some of the general terms and provisions of our common stock and our ability to issue preferred stock, including certain provisions of our second amended and restated certificate of incorporation (the “Charter”), our amended and restated bylaws (the “Bylaws”) and the Delaware General Corporation Law (the “DGCL”). This s
March 14, 2024	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Amneal Pharmaceuticals, Inc. Subsidiaries of the Registrant as of December 31, 2023: Name of Subsidiary Jurisdiction of Incorporation or Organization Amedra Pharmaceuticals LLC Delaware Amneal Healthcare Private Ltd. India Amneal Complex Products, Research LLC Delaware Amneal EU, Limited Ireland Amneal Ireland Limited Ireland Amneal Oncology Private Limited India Amneal Biosciences Pr
March 14, 2024	EX-97.1	Dodd-Frank Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K filed on March 14, 2024). Exhibit 97.1 AMNEAL PHARMACEUTICALS, INC. DODD-FRANK CLAWBACK POLICY (Effective as of October 2, 2023) I.Purpose The Board of Directors (the “Board”) of Amneal Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability. The Board therefore adopts this Dodd-Frank Cl
March 1, 2024	EX-99.1	AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2 Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income(1) of $44 million, Adjusted EBITDA(1) of $142 million; Adjusted Diluted EPS(1) of $0.14 ‒ ‒ Full Year 2023 Net Re
March 1, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2024 AMNEAL PHARMACEUTICALS, INC.
February 13, 2024	SC 13G/A	AMRX / Amneal Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0280-amnealpharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Amneal Pharmaceuticals, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 03168L105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appro
January 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 AMNEAL PHARMACEUTICALS, INC.
January 5, 2024	SC 13G	AMRX / Amneal Pharmaceuticals, Inc. / Mahesh Akram - SC 13G Passive Investment SC 13G 1 sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUS
January 3, 2024	SC 13D/A	AMRX / Amneal Pharmaceuticals, Inc. / Patel Gautam - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Gautam Patel 1 John Street, #2B Brooklyn, NY 11201 (917) 365-6300 (Name, Address and Telephone Number of Person Au
December 27, 2023	CERT	CERT Eun Ah Choi Vice President Listing Qualifications December 26, 2023 Division of Corporation Finance U.
December 26, 2023	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 AMNEAL PHARMACEUTICALS, INC. (Exact name of reg 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 AMNEAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 93-4225266 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi
December 26, 2023	25	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38485 Amneal Pharmaceuti 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38485 Amneal Pharmaceuticals, Inc., New York Stock Exchange (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registe
December 15, 2023	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 AMNEAL PHARMACEUTICALS, INC.
December 15, 2023	EX-99.1	Amneal Announces Move to Nasdaq Exhibit 99.1 Amneal Announces Move to Nasdaq • Nasdaq move will be effective on December 27, 2023 December 15, 2023 Bridgewater, N.J.– (BUSINESS WIRE) – Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSE”). The Company expects the Nasdaq listing to occur
December 15, 2023	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
December 15, 2023	EX-3.2	Amended and Restated Bylaws of Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.) (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K/A filed on December 15, 2023). Exhibit 3.2 Execution Version AMENDED AND RESTATED BYLAWS OF AMNEAL NEWCO INC. (a Delaware corporation) Effective November 7, 2023 ARTICLE I OFFICES SECTION 1. OFFICES. Amneal NewCo Inc. (the “Corporation”) shall maintain its registered office in the State of Delaware at 1209 Orange Street, City of Wilmington, County of New Castle, 19801, and its resident agent at such address is the The Corporati
December 12, 2023	SC 13G/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Fosun International Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm2332489d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value US$0.01 per share (Title of Class of Securities) 03168L105 (CUSIP Number) November 7, 2023 (Date of Event which Requires Filing of thi
December 1, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Gautam - SCHEDULE 13D/A Activist Investment SC 13D/A 1 sc13d-a.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Gautam Patel 1 John Street, #9D Brooklyn, NY 11201 (917) 365-6300 (Name, Add
November 20, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38485 Amneal Intermediate Inc. (Exact name of registrant as spec
November 14, 2023	EX-10.2	Term Loan Credit Agreement, dated as of November 14, 2023, by and among Amneal Pharmaceuticals LLC, the lenders party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent and collateral agen Exhibit 10.2 Execution Version $2,351,646,740.86 TERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, and JPMORGAN CHASE BANK, N.A., TRUIST SECURITIES, INC., BANK OF AMERICA, N.A., MUFG BANK, LTD., BARCLAYS BANK PLC, CITIGROUP GLOBAL MARKETS IN
November 14, 2023	EX-10.1	Amendment No. 2 to Term Loan Credit Agreement, dated as of November 14, 2023, among Amneal Pharmaceuticals LLC, each of the lenders party thereto, and J.P. Morgan Chase Bank, N.A. as administrative agent and collateral agen Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023 (this “Amendment”), among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Borrower”), each of the Guarantors party hereto, JPMorgan Chase Bank, N.A. (“JPM”), as administrative agent and collateral agent (in such capacities
November 14, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 AMNEAL PHARMACEUTICALS, INC.
November 14, 2023	EX-10.3	Amendment No. 1 to the Revolving Credit Agreement and Amendment No. 1 to the Collateral Agreement, dated November 14, 2023, by and among Amneal Pharmaceuticals LLC, the lenders party thereto from time to time and Truist Bank as administrative agent and collateral agen Exhibit 10.3 Execution Version AMENDMENT NO. 1 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 1 TO COLLATERAL AGREEMENT This AMENDMENT NO. 1 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 1 TO COLLATERAL AGREEMENT, dated as of November 14, 2023 (this “Amendment No. 1”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the other Loan
November 9, 2023	EX-10.2	Amendment No. 1 to Revolving Credit and Term Loan Agreement, dated as of April 20, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agent ( projectrondo-amendmentno 1 AMENDMENT NO. 1 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT AMENDMENT NO. 1 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT, dated as of April 20, 2023 (this “Amendment”), by and among RONDO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), RONDO INTERMEDIATE HOLDINGS, LLC, a Delaware lim- ited liability company (the “Borrower”), the Subsidiary Loan Parties p
November 9, 2023	EX-10.1	Amendment No. 1 to Term Loan Credit Agreement, dated as of May 30, 2023, entered into by and among Amneal Pharmaceuticals LLC, the Guarantors, and JPMorgan Chase Bank, N.A. as administrative agent ( Execution Version US-DOCS\141444271.10 AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT This AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT, dated as of May 30, 2023 (this “Amendment No. 1”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Guarantors, and JPMORGAN CHASE BANK, N.A. (“JPM”), as administrative agent (the “Administrative
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceut
November 9, 2023	EX-10.3	Amendment No. 2 Revolving Credit and Term Loan Agreement, dated as of September 21, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agen fn153-rondoxamendmentno2 1 AMENDMENT NO. 2 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT AMENDMENT NO. 2 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT, dated as of September 21, 2023 (this “Amendment”), by and among RONDO HOLDINGS, LLC, a Dela- ware limited liability company (“Holdings”), RONDO INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (the “Borrower”), the Subsidiary Loan Parti
November 8, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Chintu - SC 13D/A Activist Investment SC 13D/A 1 d581261dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Chintu Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpo
November 8, 2023	EX-10.4	Amendment No. 1 to the Tax Receivable Agreement, by and among, Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.), Amneal Pharmaceuticals, Inc. (formerly known as Amneal NewCo Inc.), Amneal Pharmaceuticals LL and Padmesh Patel, solely in his capacity as the Member Representative (Incorporated by reference to Exhibit 10.4 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2023). EX-10.4 Exhibit 10.4 AMENDMENT NO. 1 TO THE TAX RECEIVABLE AGREEMENT November 7, 2023 THIS AMENDMENT NO. 1 (this “Amendment”) to the Tax Receivable Agreement (as amended, restated or otherwise modified from time to time, the “TRA”), dated as of May 4, 2018, is adopted, executed and entered into by Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.), a Delaware corporation (th
November 8, 2023	EX-2.1	Agreement and Plan of Merger, dated as of November 7, 2023, by and among Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.), Amneal Intermediate Inc. (formerly Amneal Pharmaceuticals, Inc.) and Amneal Merger Sub 1 Inc. EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL NEWCO INC. AND AMNEAL MERGER SUB 1 INC. DATED AS OF NOVEMBER 7, 2023 Table of Contents ARTICLE I THE MERGER 3 1.1 The Merger 3 1.2 Effective Time 3 1.3 Certificate of Incorporation 3 1.4 Bylaws 3 1.5 Directors 4 1.6 Officers 4 ARTICLE II EFFECT OF MERGER ON EQUITY INTERESTS OF OLD PU
November 8, 2023	EX-3.1	Amended and Restated Certificate of Incorporation of Amneal Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Predecessor Registrant’s Current Report on Form 8-K (File No. 001-38485) filed with the Commission on November 8, 2023). EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMNEAL NEWCO INC. It is hereby certified that: 1. The present name of the corporation (hereinafter called the “Corporation”) is Amneal NewCo Inc. The Certificate of Incorporation of the Corporation was originally filed under the name Amneal NewCo Inc. with the Secretary of State of the State of Delaware on October 23, 2023. 2.
November 8, 2023	POS AM	As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration No. 333-263226 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT NO. 333-263226 UNDER THE SECURITIES ACT OF 1933 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 93-4225266 (State o
November 8, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Dipan - SC 13D/A Activist Investment SC 13D/A 1 d462495dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Dipan Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpor
November 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration No. 333-273824 Registration No. 333-248070 Registration No. 333-224700 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-273824 REGISTRATION STATEMENT NO. 333-248070 REGISTRATION STATEMENT NO. 333-224700 UNDER THE SEC
November 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration No. 333-273824 Registration No. 333-248070 Registration No. 333-224700 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-273824 REGISTRATION STATEMENT NO. 333-248070 REGISTRATION STATEMENT NO. 333-224700 UNDER THE SEC
November 8, 2023	EX-10.6	Amneal Pharmaceuticals LLC Fourth Amended and Restated Limited Liability Company Agreement, dated as of November 7, 2023, by and among Amneal Pharmaceuticals LLC and its Members EX-10.6 Exhibit 10.6 AMNEAL PHARMACEUTICALS LLC FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 7, 2023 THE COMPANY INTERESTS REPRESENTED BY THIS FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH COMPANY INTEREST
November 8, 2023	EX-10.5	Third Amended and Restated Stockholders Agreement, dated as of November 7, 2023, by and among AP Class D Member, LLC, AP Class E Member, LLC, AH PPU Management, LLC, Amneal Intermediate (formerly Amneal Pharmaceuticals, Inc. and Atlas Holdings, Inc.) and Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.) EX-10.5 Exhibit 10.5 THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT DATED AS OF NOVEMBER 7, 2023 BY AND AMONG AMNEAL GROUP (AS DEFINED HEREIN), AMNEAL PHARMACEUTICALS LLC, AMNEAL INTERMEDIATE INC. AND AMNEAL PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Certain Definitions 2 1.2 Other Terms 6 ARTICLE II TERM 7 2.1 Term and Termination 7 ARTICLE III CORPORATE GOVERNANC
November 8, 2023	EX-10.3	Amendment to No. 1, dated as of November 7, 2023, to the Employment Agreement, dated as of July 29, 2020, by and between Amneal Intermediate Inc. (formerly Amneal Pharmaceuticals, Inc.) and Nikita Shah EX-10.3 Exhibit 10.3 November 7, 2023 Nikita Shah Re: Elimination of UP-C Structure / Employment Agreement Amendment Dear Nikita: This letter agreement is intended to memorialize our agreement and understanding regarding certain technical amendments to your employment agreement (the “Employment Agreement”) with Amneal Pharmaceuticals, Inc. (“Old Pubco”) and/or Amneal Pharmaceuticals LLC (“OpCo”) i
November 8, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Tushar Bhikhubhai - SC 13D/A Activist Investment SC 13D/A 1 d567089dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Tushar Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpo
November 8, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Chirag K. - SC 13D/A Activist Investment SC 13D/A 1 d714791dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Chirag Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpo
November 8, 2023	EX-10.2	Amendment to No. 1, dated as of November 7, 2023, to the Employment Agreement, dated as of March 11, 2020, by and among Amneal Pharmaceuticals LLC, Amneal Intermediate Inc. (formerly Amneal Pharmaceuticals, Inc.) and Anastasios (Tasos) G. Konidaris EX-10.2 Exhibit 10.2 November 7, 2023 Anastasios Konidaris Re: Elimination of UP-C Structure / Employment Agreement Amendment Dear Tasos: This letter agreement is intended to memorialize our agreement and understanding regarding certain technical amendments to your employment agreement (the “Employment Agreement”) with Amneal Pharmaceuticals, Inc. (“Old Pubco”) and/or Amneal Pharmaceuticals LLC (“
November 8, 2023	EX-10.1	Amendment to No. 1, dated as of November 7, 2023, to the Employment Agreement, dated as of January 24, 2018, by and among Amneal Pharmaceuticals LLC, Amneal Holdings, LLC and Andrew Boyer, as modified EX-10.1 Exhibit 10.1 November 7, 2023 Andrew Boyer Re: Elimination of UP-C Structure / Employment Agreement Amendment Dear Andrew: This letter agreement is intended to memorialize our agreement and understanding regarding certain technical amendments to your employment agreement (the “Employment Agreement”) with Amneal Pharmaceuticals, Inc. (“Old Pubco”) and/or Amneal Pharmaceuticals LLC (“OpCo”)
November 8, 2023	EX-3.2	Amended and Restated Bylaws of Amneal Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the Predecessor Registrant’s Current Report on Form 8-K (File No. 001-38485) filed with the Commission on November 8, 2023). EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AMNEAL INTERMEDIATE INC. ARTICLE I Meetings of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from
November 8, 2023	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 20, 2023, pursuant to the provisions of Rule 12d2-2 (a).
November 8, 2023	POS AM	As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration No. 333-263225 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT NO. 333-263225 UNDER THE SECURITIES ACT OF 1933 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 93-4225266 (State o
November 8, 2023	EX-10.7	Form of Stock Surrender Agreement, dated as of November 7, 2023, by and between Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.) and former Members of Amneal Pharmaceuticals LLC EX-10.7 Exhibit 10.7 STOCK SURRENDER AGREEMENT This Stock Surrender Agreement (this “Agreement”), dated as of November 7, 2023, is made between [●] (“Member”) and Amneal NewCo Inc., a Delaware corporation (“New PubCo”). R E C I T A L S WHEREAS, pursuant to the transactions contemplated by that certain Business Combination Agreement, dated October 17, 2017, by and among Amneal Pharmaceuticals, Inc.
November 8, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Gautam - SC 13D/A Activist Investment SC 13D/A 1 d572873dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Gautam Patel c/o Tarsadia Investments, LLC Attention: Edward Coss 520 Newpo
November 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration No. 333-273824 Registration No. 333-248070 Registration No. 333-224700 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-273824 REGISTRATION STATEMENT NO. 333-248070 REGISTRATION STATEMENT NO. 333-224700 UNDER THE SEC
November 8, 2023	EX-99.1	Description of Capital Stock EX-99.1 Exhibit 99.1 DESCRIPTION OF CAPITAL STOCK General The following is a summary of some of the general terms and provisions of our common stock and our ability to issue preferred stock, including certain provisions of our second amended and restated certificate of incorporation (the “Charter”), our amended and restated bylaws (the “Bylaws”) and the Delaware General Corporation Law (the “DGCL”
November 8, 2023	8-K12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 AMNEAL PHARMACEUTICALS, INC.
November 8, 2023	EX-2.2	Agreement and Plan of Merger, dated as of November 7, 2023, by and among Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.), Amneal Pharmaceuticals LLC and Amneal Merger Sub 2 LLC EX-2.2 Exhibit 2.2 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL PHARMACEUTICALS LLC AND AMNEAL MERGER SUB 2 LLC DATED AS OF NOVEMBER 7, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 LLC Agreement 2 1.4 Managing Member 2 1.5 Officers 3 ARTICLE II EFFECT OF MERGER ON EQUITY INTERESTS OF THE COMPANY; ME
November 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 AMNEAL PHARMACEUTICALS, INC.
November 7, 2023	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income(1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted E Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income(1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Affirmed Previously Announced Increased 2023 Full Year Guidance ‒ BRIDGEWATER, NJ, November 7, 2023 - Amneal Pharmace
October 23, 2023	EX-99.1	AMNEAL REPORTS CERTAIN PRELIMINARY THIRD QUARTER 2023 FINANCIAL RESULTS AND RAISES FULL YEAR 2023 FINANCIAL GUIDANCE Exhibit 99.1 AMNEAL REPORTS CERTAIN PRELIMINARY THIRD QUARTER 2023 FINANCIAL RESULTS AND RAISES FULL YEAR 2023 FINANCIAL GUIDANCE BRIDGEWATER, NJ, October 23, 2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for t
October 23, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2023 AMNEAL PHARMACEUTICALS, INC.
October 18, 2023	EX-99.6	Term Sheet Amneal Pharmaceuticals, Inc. EX-99.6 2 d737162dex996.htm EX-99.6 Exhibit 6 EXECUTION VERSION Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group
October 18, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Dipan - SC 13D/A Activist Investment SC 13D/A 1 d547850dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Dipan Patel c/o Buckhead America Hospitality 2855 Springhill Parkway Smyrna
October 18, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Chintu - SC 13D/A Activist Investment SC 13D/A 1 d547821dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Chintu Patel c/o McCabe Heidrich & Wong, PC 4 Gatehall Drive Parsippany, NJ
October 18, 2023	EX-99.3	Term Sheet Amneal Pharmaceuticals, Inc. EX-99.3 2 d547821dex993.htm EX-99.3 Exhibit 3 EXECUTION VERSION Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group
October 18, 2023	EX-99.3	Term Sheet Amneal Pharmaceuticals, Inc. EX-99.3 2 d547850dex993.htm EXHIBIT 3 Exhibit 3 EXECUTION VERSION Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Gro
October 18, 2023	EX-99.4	Term Sheet Amneal Pharmaceuticals, Inc. EX-99.4 2 d547778dex994.htm EX-99.4 Exhibit 4 EXECUTION VERSION Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group
October 18, 2023	EX-99.7	Term Sheet Amneal Pharmaceuticals, Inc. EX-99.7 2 d547564dex997.htm EXHIBIT 7 Exhibit 7 EXECUTION VERSION Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Gro
October 18, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Chirag K. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Chirag Patel c/o McCabe Heidrich & Wong, PC 4 Gatehall Drive Parsippany, NJ 07054-4513 (908) 409-6700 (Na
October 18, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Gautam - SC 13D/A Activist Investment SC 13D/A 1 d547564dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Gautam Patel 1 John Street, #9D Brooklyn, NY 11201 (917) 365-6300 (Name, Ad
October 18, 2023	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc - Class A / Patel Tushar Bhikhubhai - SC 13D/A Activist Investment SC 13D/A 1 d547778dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L105 (CUSIP Number) Tushar Patel c/o Tarsadia Investments, LLC 520 Newport Center Drive, Twenty
October 17, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2023 AMNEAL PHARMACEUTICALS, INC.
October 17, 2023	EX-10.1	Term Sheet, dated as of October 16, 2023 among, the Company, Amneal Pharmaceuticals LLC and the Amneal Group Representative. Exhibit 10.1 Term Sheet Amneal Pharmaceuticals, Inc. This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group Representative1, on behalf of the Amneal Legacy Gr
August 9, 2023	S-8	As filed with the United States Securities and Exchange Commission on August 9, 2023 As filed with the United States Securities and Exchange Commission on August 9, 2023 Registration No.
August 9, 2023	EX-FILING FEES	Filing fee table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Amneal Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common S
August 8, 2023	EX-10.1	Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Predecessor Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (File No. 001-38485) filed with the Commission on August 8, 2023). Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (as amended and restated effective May 9, 2023) ARTICLE 1. PURPOSE The purpose of the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of Amneal Pharmaceuticals, Inc. (the “Company”) by linking the individual interests of the
August 8, 2023	EX-10.2	erm Loan Credit Agreement, dated as of May 30, 2023, Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT This AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT, dated as of May 30, 2023 (this “Amendment No. 1”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Guarantors, and JPMORGAN CHASE BANK, N.A. (“JPM”), as administrative agent (the “Administrative Agent”).
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals
August 8, 2023	EX-10.3	Amendment No.1 to Revolving Credit and Term Loan Agreement, dated as of April 20, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agent.* Exhibit 10.3 Execution Version AMENDMENT NO. 1 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT AMENDMENT NO. 1 TO REVOLVING CREDIT AND TERM LOAN AGREEMENT, dated as of April 20, 2023 (this “Amendment”), by and among RONDO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), RONDO INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (the “Borrower”), the Subsidiary Loan Parties
August 4, 2023	EX-99.1	AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income(1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income(1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Full Year Guidance ‒ BRIDGEWATER, NJ, August 4, 2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amne
August 4, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2023 AMNEAL PHARMACEUTICALS, INC.
May 19, 2023	EX-99.1	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE RUSSELL THIELE and JEFFREY ) EDELMAN, Derivatively on Behalf of ) AMNEAL PHARMACEUTICALS, ) INC., ) Plaintiffs, ) ) v. ) C.A. No. 2022-0272-LWW ) KASHIV BIOSCIENCES, LLC, ) CHINTU PATEL, CHIRAG PATEL, EX-99.1 Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE RUSSELL THIELE and JEFFREY ) EDELMAN, Derivatively on Behalf of ) AMNEAL PHARMACEUTICALS, ) INC., ) Plaintiffs, ) ) v. ) C.A. No. 2022-0272-LWW ) KASHIV BIOSCIENCES, LLC, ) CHINTU PATEL, CHIRAG PATEL, ) GAUTAM PATEL, J. KEVIN BUCHI, ) JEFF GEORGE, JOHN KIELY, and ) SHLOMO YANAI, ) ) Defendants, ) ) -and- ) ) AMNEAL PHARMACEUTIC
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 AMNEAL PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 AMNEAL PHARMACEUTICALS, INC.
May 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 AMNEAL PHARMACEUTICALS, INC.
May 9, 2023	10-Q	filed May 9, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 9, 2023	EX-10.3	Modification No. 2 to Employment Agreement, dated February Exhibit 10.3 MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED FEBRUARY 6, 2018 This Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Andrew Boyer (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment Agreement
May 9, 2023	EX-10.1	by and among Amneal Pharmaceuticals, Inc. and Exhibit 10.1 MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED MARCH 11, 2020 This Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Anastasios G. Konidaris (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment
May 9, 2023	EX-10.2	by and among Amneal Pharmaceuticals, Inc. and Exhibit 10.2 MODIFICATION No. 1 to EMPLOYMENT AGREEMENT ENTERED July 29, 2020 This Modification, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Nikita Shah (the “Executive” and, collectively with Amneal, the “Parties”). WHEREAS, the Company and the Executive executed that certain Employment Agreement dated Jul
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2023 AMNEAL PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2023 AMNEAL PHARMACEUTICALS, INC.
May 5, 2023	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS ‒ Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS ‒ Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Year Guidance ‒ BRIDGEWATER, NJ, May 5, 2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actua
April 17, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2023 AMNEAL PHARMACEUTICALS, INC.
April 17, 2023	EX-99.1	AMNEAL REPORTS CERTAIN PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS AND AFFIRMS FULL YEAR 2023 FINANCIAL GUIDANCE Exhibit 99.1 AMNEAL REPORTS CERTAIN PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS AND AFFIRMS FULL YEAR 2023 FINANCIAL GUIDANCE BRIDGEWATER, NJ, April 17, 2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year e
March 24, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 24, 2023	DEF 14A	Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 6, 2023	POS AM	As filed with the Securities and Exchange Commission on March 3, 2023 POS AM Table of Contents As filed with the Securities and Exchange Commission on March 3, 2023 Registration No.
March 6, 2023	POS AM	As filed with the Securities and Exchange Commission on March 3, 2023 POS AM 1 d447320dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 3, 2023 Registration No. 333-263225 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMNEAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its char
March 3, 2023	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Amneal Pharmaceuticals, Inc. Subsidiaries of the Registrant as of December 31, 2022: Name of Subsidiary Jurisdiction of Incorporation or Organization Amedra Pharmaceuticals LLC Delaware Amneal Healthcare Private Ltd. India Amneal Complex Products, Research LLC Delaware Amneal EU, Limited Ireland Amneal Injectables Private Limited India Amneal Ireland Limited Ireland Amneal Oncology Pr
March 3, 2023	10-K	Annual Report on Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal P
March 2, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) AMNEAL PHARMACEUTICALS, INC.
March 2, 2023	POSASR	As filed with the Securities and Exchange Commission on March 2, 2023 POSASR Table of Contents As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.
March 2, 2023	EX-24.2	Power of Attorney of Deborah M. Autor. EX-24.2 Exhibit 24.2 POWER OF ATTORNEY January 18, 2023 I hereby authorize and appoint Chirag Patel, Chintu Patel and Anastasios Konidaris, and each of them, with full power of substitution and resubstitution and full power to act without the other, as my true and lawful attorney-in-fact and agent to act in my name, place and stead and to execute in my name and on my behalf, individually and in my
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 AMNEAL PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 AMNEAL PHARMACEUTICALS, INC.
March 2, 2023	EX-24.2	Power of Attorney of Deborah M. Autor. Exhibit 24.2 POWER OF ATTORNEY January 18, 2023 I hereby authorize and appoint Chirag Patel, Chintu Patel and Anastasios Konidaris, and each of them, with full power of substitution and resubstitution and full power to act without the other, as my true and lawful attorney-in-fact and agent to act in my name, place and stead and to execute in my name and on my behalf, individually and in my capacit
March 2, 2023	POSASR	As filed with the Securities and Exchange Commission on March 2, 2023 POSASR Table of Contents As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.
March 2, 2023	EX-99.1	AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ‒ Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03 ‒ ‒ Q4 2022 Adjusted Net Income of $71 million (1), Adjusted EBITDA (1) of $154 mil Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ‒ Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03 ‒ ‒ Q4 2022 Adjusted Net Income of $71 million (1), Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.23 ‒ ‒ Full Year 2022 Net Revenue of $2.21 billion; GAAP Net Loss of $130 million; Diluted Loss per
March 2, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) AMNEAL PHARMACEUTICALS, INC.
February 9, 2023	SC 13G/A	AMRX / Amneal Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Amneal Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03168L105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is
January 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2023 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2023 AMNEAL PHARMACEUTICALS, INC.
December 14, 2022	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc / TPG GP A, LLC - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Titles of Class of Securities) 03168L105 (CUSIP Number) Bradford Berenson TPG Inc. 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, Ad
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceut
November 4, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2022 AMNEAL PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2022 AMNEAL PHARMACEUTICALS, INC.
November 4, 2022	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS ‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS ‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook ‒ BRIDGEWATER, NJ, November 4, 2022 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced i
September 6, 2022	EX-10.1	Agreement by and among Amneal Pharmaceuticals, Inc and Gustavo Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is entered into as of September 1, 2022, by and between Amneal Pharmaceuticals, Inc. (?Amneal? or the ?Company?) and Gustavo Pesquin (the ?Executive? and, collectively the ?Parties?). WITNESSETH: WHEREAS, effective September 6, 2022 (the ?Effective Date?), the Company desires to employ the Executive as Executive Vice Preside
September 6, 2022	EX-99.1	Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty Exhibit 99.1 Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer ? Specialty September 6, 2022 BRIDGEWATER, N.J. ? Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (?Amneal? or the ?Company?) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Mr. Pesquin joins the Company from S
September 6, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2022 AMNEAL PHARMACEUTICALS, INC.
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals
August 8, 2022	EX-10.1	Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended Exhibit 10.1 AMNEAL PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As amended and restated on August 4, 2022 Non?employee members of the board of directors (the ?Board?) of Amneal Pharmaceuticals, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non? Employee Director Compensation Policy (this ?Policy?). The cash and equity compen
August 5, 2022	EX-99.1	AMNEAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS ‒ Q2 2022 Net Revenue of $559 million; GAAP Net Loss of $121 million; Diluted Loss per Share of $(0.80) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Updates 2022 A Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS ? Q2 2022 Net Revenue of $559 million; GAAP Net Loss of $121 million; Diluted Loss per Share of $(0.80) ? ? Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.19 ? ? Updates 2022 Adjusted EBITDA guidance ? BRIDGEWATER, NJ, August 5, 2022 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (?Amneal? or the ?Company?) announc
August 5, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2022 AMNEAL PHARMACEUTICALS, INC.
August 5, 2022	LETTER	LETTER United States securities and exchange commission logo August 5, 2022 Anastasios Konidaris Chief Financial Officer Amneal Pharmaceuticals, Inc.
August 4, 2022	CORRESP	Via EDGAR Via EDGAR August 4, 2022 Mr. Eric Atallah Ms. Lynn Dicker U.S. Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Amneal Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 1, 2022 File No. 001-38485 Dear Mr. Atallah and Ms. Dicker: Amneal Pharmaceuticals, Inc. (the ?Company,? ?w
August 3, 2022	EX-99.1	Amneal Appoints Deborah M. Autor to Board of Directors - Adds new independent director with deep biopharmaceutical industry expertise in quality, regulatory and policy Exhibit 99.1 Amneal Appoints Deborah M. Autor to Board of Directors - Adds new independent director with deep biopharmaceutical industry expertise in quality, regulatory and policy August 3, 2022 BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2
August 3, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2022 AMNEAL PHARMACEUTICALS, INC.
July 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2022 AMNEAL PHARMACEUTICALS, INC.
June 27, 2022	LETTER	LETTER United States securities and exchange commission logo June 27, 2022 Anastasios Konidaris Chief Financial Officer Amneal Pharmaceuticals, Inc.
June 2, 2022	EX-10.1	Revolving Credit Agreement, dated as of June 2, 2022, by and among Amneal Pharmaceuticals LLC, as the borrower, Truist Bank, as administrative agent and collateral agent and the lenders and other parties party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 2, 2022) Execution Version AmericasActive:17030364.10 $350,000,000 REVOLVING CREDIT AGREEMENT, dated as of June 2, 2022, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, TRUIST BANK as Administrative Agent and Collateral Agent, TRUIST SECURITIES, INC., JPMORGAN CHASE BANK, N.A., and BANK OF AMERICA, N.A. as Bookrunners, Joint Lead Arrangers and as Co-Syndication Agents and MUFG
June 2, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2022 AMNEAL PHARMACEUTICALS, INC.
June 2, 2022	EX-10.2	ABL Guarantee and Collateral Agreement, dated as of June 2, 2022, by and among the loan parties from time-to-time party thereto and Truist Bank, as administrative agent and collateral agent. Execution Version AmericasActive:16964714.2 ABL GUARANTEE AND COLLATERAL AGREEMENT, dated as of June 2, 2022, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, each other Grantor party hereto, and TRUIST BANK, as Administrative Agent and Collateral Agent Reference is made to the ABL/Term Loan Intercreditor Agreement dated as of May 4, 2018 by and among JPMorgan Chase Bank, N.A., as ?ABL Agent? pr
May 13, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 AMNEAL PHARMACEUTICALS, INC.
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 4, 2022	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS ‒ Q1 2022 Net Revenue of $498 million; GAAP Net Loss of $2 million; Diluted Loss per Share of $(0.01) ‒ ‒ Adjusted EBITDA (1) of $100 million includes $5 million of R&D milestone expense; Adjusted D Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS ? Q1 2022 Net Revenue of $498 million; GAAP Net Loss of $2 million; Diluted Loss per Share of $(0.01) ? ? Adjusted EBITDA (1) of $100 million includes $5 million of R&D milestone expense; Adjusted Diluted EPS (1) of $0.12 ? ? Maintaining 2022 Full Year Outlook ? BRIDGEWATER, NJ, May 4, 2022 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
May 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2022 AMNEAL PHARMACEUTICALS, INC.
March 25, 2022	DEF 14A	Safe Harbor Statement Corporate Governance Proposal 1 Election of Directors Our Management Executive Compensation Proposal 2 Advisory Vote on Executive Compensation Security Ownership of Certain Beneficial Owners and Management Certain Related Partie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Prox
March 25, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 AMNEAL PHARMACEUTICALS, INC.
March 2, 2022	S-3ASR	As filed with the Securities and Exchange Commission on March 2, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No.
March 2, 2022	S-3ASR	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No.
March 2, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) AMNEAL PHARMACEUTICALS, INC.
March 2, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) AMNEAL PHARMACEUTICALS, INC.
March 2, 2022	EX-99.1	AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS ‒ Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04 ‒ ‒ Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 mil Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS ‒ Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04 ‒ ‒ Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.18 ‒ ‒ Full Year Net Revenue of $2.1 billion; GAAP Net Income of $11 million; Diluted EPS of $0.07 ‒
March 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2022 AMNEAL PHARMACEUTICALS, INC.
March 2, 2022	EX-4.4	Form of Indenture. Exhibit 4.4 AMNEAL PHARMACEUTICALS, INC. INDENTURE Dated as of [, 20] [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Es
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal P
March 1, 2022	EX-2.5	Share Purchase Agreement, dated November 2, 2021, by and among Puniska Healthcare Pvt. Ltd. and Amneal Pharmaceuticals Private Limited. Exhibit 2.5 IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE COMMISSION RULES, CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. BRACKETS WITH ASTERISKS DENOTE OMISSIONS (i.e., [***]). SHARE PURCHASE AGREEMENT AMONGST AMNEAL PHARMACEUTICALS PRIVATE LIMITED AND THE PERSONS LISTED IN SCHEDULE
March 1, 2022	EX-21.1	Subsidiaries of the registrant. Exhibit 21.1 Amneal Pharmaceuticals, Inc. Subsidiaries of the Registrant as of December 31, 2021: Name of Subsidiary Jurisdiction of Incorporation or Organization Amedra Pharmaceuticals LLC Delaware Amneal Biologics Private Ltd. India Amneal Biosciences LLC Delaware Amneal Complex Products, Research LLC Delaware Amneal EU, Limited Ireland Amneal Injectables Private Limited India Amneal Ireland Lim
February 9, 2022	SC 13G/A	AMRX / Amneal Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Amneal Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03168L105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is
January 19, 2022	SC 13D/A	AMRX / Amneal Pharmaceuticals Inc / TPG GP A, LLC - AMENDED SC13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amneal Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Titles of Class of Securities) 03168L105 (CUSIP Number) Bradford Berenson TPG Inc. 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, A
January 11, 2022	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2022 AMNEAL PHARMACEUTICALS, INC.
January 5, 2022	EX-99.1	Amneal Acquires Saol Therapeutics’ Baclofen Franchise EX-99.1 Exhibit 99.1 Amneal Acquires Saol Therapeutics’ Baclofen Franchise - Expands Amneal’s Neurology Presence into Spasticity January 5, 2022 BRIDGEWATER, N.J. and ROSWELL, GA —(BUSINESSWIRE)— Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol
January 5, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2021 AMNEAL PHARMACEUTICALS, INC.
January 5, 2022	EX-2.1	Asset Purchase Agreement, dated December 30, 2021, by and among Amneal and Saol Therapeutics. Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT AMONG SAOL INTERNATIONAL LIMITED, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., SAOL INTERNATIONAL RESEARCH LIMITED, SAOL INTERNATIONAL DEVELOPMENT LIMITED, EMERALD INTERNATIONAL LIMITED, EMERALD THERAPEUTICS RESEARCH LIMITED AND AMNEAL PHARMACEUTICALS LLC Dated as of December 30, 2021 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceut
November 3, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 AMNEAL PHARMACEUTICALS, INC.
November 3, 2021	EX-99.1	AMNEAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS ‒ Q3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21 ‒ ‒ Updating 2021 F Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS ? Q3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03) ? ? Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21 ? ? Updating 2021 Full Year Financial Outlook, Including Raising Adjusted EBITDA and Adjusted EPS Guidance ? ? Announces Acquisition of Puniska Healthcare t
August 9, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 AMNEAL PHARMACEUTICALS, INC.
August 9, 2021	EX-99.1	AMNEAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS ‒ Q2 2021 Net Revenue of $535 million; GAAP Net Income of $15 million; Diluted Income per Share of $0.10 ‒ ‒ Adjusted EBITDA (1) of $151 million; Adjusted Diluted EPS (1) of $0.25 ‒ ‒ Maintaining 2 Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS ? Q2 2021 Net Revenue of $535 million; GAAP Net Income of $15 million; Diluted Income per Share of $0.10 ? ? Adjusted EBITDA (1) of $151 million; Adjusted Diluted EPS (1) of $0.25 ? ? Maintaining 2021 Full Year Financial Outlook ? BRIDGEWATER, NJ, August 9, 2021 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ?Company?) announced i
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals
August 9, 2021	EX-10.1	Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended and restated on May 5, 2021 Exhibit 10.1 AMNEAL PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As amended and restated on May 5, 2021 Non?employee members of the board of directors (the ?Board?) of Amneal Pharmaceuticals, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non? Employee Director Compensation Policy (this ?Policy?). The cash and equity compensat
May 10, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 AMNEAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38485 32-0546926 (State or other jurisdiction of incorporation) (Commissio
May 7, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2021 AMNEAL PHARMACEUTICALS, INC.
May 7, 2021	EX-3.1	Second Amended and Restated Certificate of Incorporation of Amneal Pharmaceuticals, Inc. adopted as of May 5, 2021. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMNEAL PHARMACEUTICALS, INC. It is hereby certified that: 1. The present name of the corporation (hereinafter called the ?Corporation?) is AMNEAL PHARMACEUTICALS, INC. The Certificate of Incorporation of the Corporation was originally filed under the name Atlas Holdings, Inc. with the Secretary of State of the State of Delawar
May 7, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceutical
May 7, 2021	EX-10.2	Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated as of July 29, 2020. Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is entered into as of July 29, 2020, by and among Amneal Pharmaceuticals, Inc. (the ?Company?) and Nikita Shah (the ?Executive? and, collectively with the Company, the ?Parties?). WITNESSETH: WHEREAS, the Executive is currently employed by the Company as Senior Vice President, Chief Human Resources Officer (?CHRO?); WHEREAS,
May 7, 2021	EX-10.1	Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is entered into as of July 29, 2020, by and among Amneal Pharmaceuticals, Inc. (the ?Company?) and Joseph Todisco (the ?Executive? and, collectively with the Company, the ?Parties?). WITNESSETH: WHEREAS, the Executive is currently employed by the Company as Senior Vice President, Sales & Marketing; WHEREAS, effective August
May 7, 2021	EX-99.1	AMNEAL REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS ‒ Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.20 ‒ ‒ Maintaining 202 Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS ? Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per Share of $0.04 ? ? Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.20 ? ? Maintaining 2021 Full Year Financial Outlook ? BRIDGEWATER, NJ, May 7, 2021 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ?Company?) announced its re

AMRX / Amneal Pharmaceuticals, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings